Adamas Pharmaceuticals Long Term Debt

Adamas Pharmaceuticals (ADMS) currently reports a long-term debt of $120M as of September 2021. That compares with $130M in the prior-year period — down 1.7% year over year. Use the charts on this page to explore Adamas Pharmaceuticals's long-term debt history and peer comparisons.

Adamas Pharmaceuticals's long-term debt decreased from $130M to $120M — a 1.7% year-over-year decrease (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adamas Pharmaceuticals reported $120M in long-term debt as of September 2021. That compares with $130M in the prior-year period — down 1.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adamas Pharmaceuticals, and consider following ADMS for alerts when major investors trade the stock.

Adamas Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADMS with unrelated industries.